RU2008130043A - Комбинация, включающая комбретастатин и противораковые средства - Google Patents
Комбинация, включающая комбретастатин и противораковые средства Download PDFInfo
- Publication number
- RU2008130043A RU2008130043A RU2008130043/15A RU2008130043A RU2008130043A RU 2008130043 A RU2008130043 A RU 2008130043A RU 2008130043/15 A RU2008130043/15 A RU 2008130043/15A RU 2008130043 A RU2008130043 A RU 2008130043A RU 2008130043 A RU2008130043 A RU 2008130043A
- Authority
- RU
- Russia
- Prior art keywords
- combretastatin
- effective amount
- combination
- treatment
- cancer agents
- Prior art date
Links
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 title claims abstract 9
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 title claims abstract 9
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract 4
- 230000001093 anti-cancer Effects 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Фармацевтическая комбинация, содержащая эффективное количество противоракового соединения, выбранного из группы, состоящей из VEGF Trap, в комбинации с эффективным количеством комбретастатина для лечения солидных опухолей. ! 2. Фармацевтическая комбинация, содержащая эффективное количество противоракового соединения, выбранного из группы, состоящей из VEGF Trap, в комбинации с эффективным количеством комбретастатина для лечения солидных опухолей, где указанный комбретастатин отвечает следующей формуле: ! ! 3. Комбинация по п.2, где указанный комбретастатин находится в виде гидрохлорида.
Claims (3)
1. Фармацевтическая комбинация, содержащая эффективное количество противоракового соединения, выбранного из группы, состоящей из VEGF Trap, в комбинации с эффективным количеством комбретастатина для лечения солидных опухолей.
2. Фармацевтическая комбинация, содержащая эффективное количество противоракового соединения, выбранного из группы, состоящей из VEGF Trap, в комбинации с эффективным количеством комбретастатина для лечения солидных опухолей, где указанный комбретастатин отвечает следующей формуле:
3. Комбинация по п.2, где указанный комбретастатин находится в виде гидрохлорида.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0513114 | 2005-12-22 | ||
| FR0513114A FR2895258B1 (fr) | 2005-12-22 | 2005-12-22 | Combinaison comprenant de la combretastatine et des agents anticancereux |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008130043A true RU2008130043A (ru) | 2010-01-27 |
| RU2396952C2 RU2396952C2 (ru) | 2010-08-20 |
Family
ID=37054578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008130043/15A RU2396952C2 (ru) | 2005-12-22 | 2006-12-18 | Комбинация, включающая комбретастатин и противораковые средства |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7851443B2 (ru) |
| EP (1) | EP1965784A1 (ru) |
| JP (1) | JP2009520774A (ru) |
| KR (1) | KR20080099234A (ru) |
| CN (1) | CN101346137B (ru) |
| AU (1) | AU2006334306B2 (ru) |
| BR (1) | BRPI0620242A2 (ru) |
| CA (1) | CA2631108A1 (ru) |
| FR (1) | FR2895258B1 (ru) |
| HK (1) | HK1128234A1 (ru) |
| IL (1) | IL192144A0 (ru) |
| RU (1) | RU2396952C2 (ru) |
| WO (1) | WO2007077309A1 (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090209496A1 (en) * | 2008-02-15 | 2009-08-20 | David Chaplin | Methods and compositions for enhancing the efficacy of rtk inhibitors |
| FR2945210B1 (fr) * | 2009-05-07 | 2011-07-01 | Sanofi Aventis | Combinaison antitumorale comprenant l'ave8062 et le sorafenib |
| EP2407161A1 (en) | 2010-07-13 | 2012-01-18 | Sanofi | An antitumoral combination comprising ombrabulin and bevacizumab |
| FR2968557A1 (fr) | 2010-12-09 | 2012-06-15 | Sanofi Aventis | Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab |
| FR2978662A1 (fr) | 2011-08-01 | 2013-02-08 | Sanofi Sa | Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie |
| FR2978663A1 (fr) | 2011-08-01 | 2013-02-08 | Sanofi Sa | Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie |
| US9458086B1 (en) | 2013-07-03 | 2016-10-04 | University Of South Florida (A Florida Non-Profit Corporation) | Compositions and methods for adipocyte modulation |
| CN108727222B (zh) * | 2017-04-24 | 2020-12-08 | 延边大学 | 一种选择性抗癌活性的tyd1608及其制备及用途 |
| CN112739323A (zh) | 2018-05-10 | 2021-04-30 | 瑞泽恩制药公司 | 含有高浓度vegf受体融合蛋白的制剂 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4996237A (en) * | 1987-01-06 | 1991-02-26 | Arizona Board Of Regents | Combretastatin A-4 |
| US5430062A (en) * | 1992-05-21 | 1995-07-04 | Research Corporation Technologies, Inc. | Stilbene derivatives as anticancer agents |
| US5731353A (en) * | 1993-09-08 | 1998-03-24 | Ajinomoto Co., Inc. | Stilbene derivatives and pharmaceutical compositions containing them |
| TW325458B (en) * | 1993-09-08 | 1998-01-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer |
| US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| US5561122A (en) * | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
| TW334418B (en) * | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
| ATE328599T1 (de) * | 1998-04-03 | 2006-06-15 | Ajinomoto Kk | Antitumorale mittel |
| CZ302689B6 (cs) | 1999-06-08 | 2011-09-07 | Regeneron Pharmaceuticals, Inc. | Izolovaná molekula nukleové kyseliny, fúzní polypeptid jí kódovaný, vektor s jejím obsahem, systém vektor-hostitel pro produkci fúzního polypeptidu a zpusob jeho prípravy, antagonista dimerního VEGF a použití |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| DE60115044T2 (de) | 2000-06-30 | 2006-08-03 | Inex Pharmaceuticals Corp., Burnaby | Liposomale antineoplastische arzneimittel und deren verwendungen |
| US20020183266A1 (en) * | 2001-03-15 | 2002-12-05 | Aventis Pharma, S.A. | Combination comprising combretastatin and anticancer agents |
| EP1438281A4 (en) * | 2001-10-26 | 2006-04-26 | Oxigene Inc | FUNCTIONALIZED STYLENE DERIVATIVES AS IMPROVED MEDIUM-TERM MEDICAL DEVICES |
| CN1798544A (zh) | 2003-04-02 | 2006-07-05 | 塞拉特药物股份有限公司 | 喜树碱和氟嘧啶的组合物 |
| EP1631317A2 (en) * | 2003-06-06 | 2006-03-08 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for tumor regression |
| AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| BRPI0414698A (pt) * | 2003-09-23 | 2006-11-28 | Novartis Ag | combinação de um inibidor receptor de vegf com um agente quimioterapêutico |
-
2005
- 2005-12-22 FR FR0513114A patent/FR2895258B1/fr not_active Expired - Fee Related
-
2006
- 2006-12-18 BR BRPI0620242-0A patent/BRPI0620242A2/pt not_active IP Right Cessation
- 2006-12-18 CN CN2006800485720A patent/CN101346137B/zh not_active Expired - Fee Related
- 2006-12-18 KR KR1020087014997A patent/KR20080099234A/ko not_active Application Discontinuation
- 2006-12-18 RU RU2008130043/15A patent/RU2396952C2/ru not_active IP Right Cessation
- 2006-12-18 WO PCT/FR2006/002771 patent/WO2007077309A1/fr active Application Filing
- 2006-12-18 JP JP2008546511A patent/JP2009520774A/ja active Pending
- 2006-12-18 EP EP06841974A patent/EP1965784A1/fr not_active Withdrawn
- 2006-12-18 CA CA002631108A patent/CA2631108A1/fr not_active Abandoned
- 2006-12-18 AU AU2006334306A patent/AU2006334306B2/en not_active Ceased
-
2008
- 2008-06-12 IL IL192144A patent/IL192144A0/en unknown
- 2008-06-19 US US12/142,130 patent/US7851443B2/en not_active Expired - Fee Related
-
2009
- 2009-07-06 HK HK09106054.1A patent/HK1128234A1/xx not_active IP Right Cessation
-
2010
- 2010-11-09 US US12/942,655 patent/US20110054035A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007077309A1 (fr) | 2007-07-12 |
| RU2396952C2 (ru) | 2010-08-20 |
| AU2006334306A1 (en) | 2007-07-12 |
| JP2009520774A (ja) | 2009-05-28 |
| US20090023656A1 (en) | 2009-01-22 |
| IL192144A0 (en) | 2008-12-29 |
| CN101346137A (zh) | 2009-01-14 |
| EP1965784A1 (fr) | 2008-09-10 |
| BRPI0620242A2 (pt) | 2011-11-08 |
| CA2631108A1 (fr) | 2007-07-12 |
| US20110054035A1 (en) | 2011-03-03 |
| US7851443B2 (en) | 2010-12-14 |
| FR2895258A1 (fr) | 2007-06-29 |
| FR2895258B1 (fr) | 2008-03-21 |
| KR20080099234A (ko) | 2008-11-12 |
| AU2006334306B2 (en) | 2012-08-30 |
| CN101346137B (zh) | 2011-09-21 |
| HK1128234A1 (en) | 2009-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008130043A (ru) | Комбинация, включающая комбретастатин и противораковые средства | |
| RU2008139905A (ru) | Фармацевтическая композиция для наружного применения | |
| BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
| RU2014112319A (ru) | Соединения и фармацевтические композиции для лечения вирусных инфекций | |
| EA200800172A1 (ru) | 2,4-диаминопиримидины как ингибиторы aurora | |
| EA201001680A1 (ru) | Соединения бензолсульфонамидтиазола и оксазола | |
| EA201000050A1 (ru) | Замещенные бициклолактамные соединения | |
| EP2277595A3 (en) | Compounds for immunopotentiation | |
| NO20073790L (no) | Kjemiske forbindelser | |
| NO20073788L (no) | Kjemiske forbindelser | |
| AR049681A1 (es) | Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas | |
| EA200801560A1 (ru) | Бифенилкарбоксамиды | |
| CY1111022T1 (el) | Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων | |
| BRPI0714885B8 (pt) | compostos terapêuticos e seu uso | |
| RU2008112676A (ru) | Противоопухолевое средство | |
| EA200970124A1 (ru) | Производные 2-арилиндола в качестве ингибиторов npges-1 | |
| EA200602281A1 (ru) | Гетероарилсульфоны и сульфонамиды и их терапевтические применения | |
| EA200901164A1 (ru) | КОНДЕНСИРОВАННЫЕ ПИРИМИДИНОНЫ В КАЧЕСТВЕ ЛИГАНДОВ mGLUR | |
| EA200900269A1 (ru) | Лекарственные комбинации для лечения заболеваний дыхательных путей | |
| RU2009138470A (ru) | Композиция для наружного применения на коже | |
| EP1872780A3 (en) | Omega-Phenyloctanamides as therapeutic compounds | |
| RU2009127858A (ru) | Фармацевтическая композиция, включающая алискирен и авосентан | |
| RU2008102251A (ru) | Аналоги тиоколхикозида с миорелаксантной и противовоспалительной активностью | |
| EA200701881A1 (ru) | 1,3-тиазол-5-карбоксамиды, используемые в качестве противораковых химиотерапевтических агентов | |
| JP2008545013A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20131219 |